2023
Bradykinin B2 receptor blockade and intradialytic hypotension
Gamboa J, Mambungu C, Clagett A, Nian H, Yu C, Ikizler T, Brown N. Bradykinin B2 receptor blockade and intradialytic hypotension. BMC Nephrology 2023, 24: 134. PMID: 37170244, PMCID: PMC10176680, DOI: 10.1186/s12882-023-03192-4.Peer-Reviewed Original ResearchConceptsBradykinin B2 receptor blockadeB2 receptor blockadeMaintenance hemodialysisBlood pressureReceptor blockersReceptor blockadeIntradialytic hypotensionBradykinin B2 receptor blockerLack of vasoconstrictionProduction of vasodilatorsSystolic blood pressureGroup of patientsCrossover clinical trialCommon clinical complicationHemodynamic effectsClinical complicationsContinuous infusionClinical trialsStratified analysisIcatibantHemodialysisPatientsHypotensionPlaceboCompensatory mechanismsCancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association
Cohen J, Brown N, Brown S, Dent S, van Dorst D, Herrmann S, Lang N, Oudit G, Touyz R, Arteriosclerosis T. Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension 2023, 80: e46-e57. PMID: 36621810, PMCID: PMC10602651, DOI: 10.1161/hyp.0000000000000224.Peer-Reviewed Original ResearchConceptsCardiovascular toxicityVascular endothelial growth factor inhibitorsCancer therapyEvidence-based clinical trialsNational hypertension guidelinesVascular endothelial growth factor receptorCardiovascular risk factorsDiscontinuation of treatmentCommon side effectsGrowth factor inhibitorsEndothelial growth factor receptorPrimary care professionalsAmerican Heart AssociationTyrosine kinase inhibitorsOptimal therapeutic effectNitric oxide generationGrowth factor receptorHypertension specialistsHypertension guidelinesSympathetic outflowAdjunctive therapyCardiovascular mortalityEndothelial dysfunctionHormone therapyBlood pressure
2022
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment
Wilson JR, Garner EM, Mashayekhi M, Hubers SA, Bustamante C, Kerman SJ, Nian H, Shibao CA, Brown NJ. DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment. Hypertension 2022, 79: 827-835. PMID: 35045722, PMCID: PMC8917054, DOI: 10.1161/hypertensionaha.121.18348.Peer-Reviewed Original ResearchMeSH KeywordsAdultAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensinsAprepitantBlood PressureCardiovascular AgentsCatecholaminesCross-Over StudiesDiabetes Mellitus, Type 2Dipeptidyl Peptidase 4HumansNorepinephrineRamiprilRenin-Angiotensin SystemSitagliptin PhosphateValsartanConceptsDPP4 inhibitionBlood pressureACE inhibitionDouble-blind crossover studyAcute ACE inhibitionBlood pressure armNK1 receptor blockerACE inhibitor treatmentOral diabetes medicationsCalcium channel blockersType 2 diabetesEffects of DPP4Aldosterone systemCardiovascular complicationsDiabetes medicationsReceptor blockersCardiovascular effectsCrossover therapyHeart failureHypotensive effectCrossover studyChannel blockersDPP4 inhibitorsHeart rateInhibitor treatment
2019
Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition
Wilson JR, Kerman SJ, Hubers SA, Yu C, Nian H, Grouzmann E, Eugster PJ, Mayfield DS, Brown NJ. Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition. Journal Of The Endocrine Society 2019, 3: 1784-1798. PMID: 31528826, PMCID: PMC6734191, DOI: 10.1210/js.2019-00185.Peer-Reviewed Original ResearchPostprandial blood pressureDPP4 inhibitionNPY 1Blood pressureHeart failureACE inhibitionSubstance PVasoactive peptidesPostprandial glucagon-like peptide-1Substance P receptor blockadeDipeptidyl peptidase-4 inhibitorsGlucagon-like peptide-1Mixed-meal studyAngiotensin receptor blockersDouble-blind treatmentPeptidase-4 inhibitorsType 2 diabetesReceptor-dependent mechanismAntihypertensive groupNPY 3Y1 agonistRAAS inhibitionReceptor blockersReceptor blockadeACE inhibitors
2018
Early urine electrolyte patterns in patients with acute heart failure
Collins SP, Jenkins CA, Baughman A, Miller KF, Storrow AB, Han JH, Brown NJ, Liu D, Luther JM, McNaughton CD, Self WH, Peng D, Testani JM, Lindenfeld J. Early urine electrolyte patterns in patients with acute heart failure. ESC Heart Failure 2018, 6: 80-88. PMID: 30295437, PMCID: PMC6351901, DOI: 10.1002/ehf2.12368.Peer-Reviewed Original ResearchConceptsAcute heart failureDiuretic administrationDiuretic resistanceHeart failureLoop diureticsLow urinary sodiumEscalation of therapyUrine sodium excretionSubset of patientsSystolic blood pressureEmergency department patientsUrine sodium concentrationAHF diagnosisAHF patientsIntravenous diureticsUrinary sodiumED staySodium excretionUrinary electrolytesUrine sodiumNatriuretic responseStandard therapyBlood pressureDepartment patientsUrine outputCharacteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case−control study
Shuey MM, Gandelman JS, Chung CP, Nian H, Yu C, Denny JC, Brown NJ. Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case−control study. BMJ Open 2018, 8: e021640. PMID: 29950471, PMCID: PMC6020960, DOI: 10.1136/bmjopen-2018-021640.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAdultAgedAngiotensin Receptor AntagonistsAntihypertensive AgentsBlack or African AmericanBlood PressureCalcium Channel BlockersCase-Control StudiesDiabetes Mellitus, Type 2Electronic Health RecordsFemaleHumansHypertensionLogistic ModelsMaleMiddle AgedMultivariate AnalysisPrevalenceTennesseeWhite PeopleConceptsElectronic health recordsResistant hypertensionBlood pressureChronic kidney disease stage 3Mineralocorticoid receptor antagonist useClinical treatmentDihydropyridine calcium channel blockerAntihypertensive medication classesControlled blood pressureOutpatient blood pressureTotal hypertensive populationAngiotensin receptor blockersTransient ischemic attackDisease stage 3Health recordsMineralocorticoid receptor antagonistsReceptor antagonist useHigh blood pressureIschemic heart diseaseAlpha-2 agonistsBody mass indexCalcium channel blockersAfrican American patientsNumber of patientsType 2 diabetes
2017
Two Pools of Epoxyeicosatrienoic Acids in Humans
Elijovich F, Milne GL, Brown NJ, Laniado-Schwartzman M, Laffer CL. Two Pools of Epoxyeicosatrienoic Acids in Humans. Hypertension 2017, 71: 346-355. PMID: 29279315, PMCID: PMC5764817, DOI: 10.1161/hypertensionaha.117.10392.Peer-Reviewed Original ResearchConceptsSalt-resistant subjectsDihydroxyeicosatrienoic acidsEpoxyeicosatrienoic acidsBlood pressurePlasma epoxyeicosatrienoic acidsRegulation of natriuresisSalt-sensitive subjectsUrine sodium excretionPotential therapeutic implicationsRenal poolSodium excretionInpatient protocolNormotensive subjectsFractional excretionVascular dysfunctionVascular toneSystemic originTherapeutic implicationsTotal poolNatriuresisSalt loadingExcretionUrine poolsAldosteroneCatecholaminesHypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin
Wilson JR, Shuey MM, Brown NJ, Devin JK. Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin. Journal Of The Endocrine Society 2017, 1: 1168-1178. PMID: 29264572, PMCID: PMC5686657, DOI: 10.1210/js.2017-00312.Peer-Reviewed Original ResearchDPP4 activityHealthy controlsSitagliptin doseSystolic blood pressurePeptidase-4 inhibitorsType 2 diabetesDipeptidyl peptidase-4Blood pressureCrossover fashionMetabolic syndromeCrossover studyMultivariable analysisDPP4 inhibitionDPP4 inhibitorsHypertensionPlaceboPeptidase-4High dosesSitagliptinT2DMDecreased inhibitionPatientsLaboratory dataInfluences responseDiabetesSystolic Blood Pressure and Biochemical Assessment of Adherence
McNaughton CD, Brown NJ, Rothman RL, Liu D, Kabagambe EK, Levy PD, Self WH, Storrow AB, Collins SP, Roumie CL. Systolic Blood Pressure and Biochemical Assessment of Adherence. Hypertension 2017, 70: 307-314. PMID: 28652467, PMCID: PMC5531074, DOI: 10.1161/hypertensionaha.117.09659.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsBiomarkersBlood PressureBlood Pressure DeterminationCross-Sectional StudiesEmergency Medical ServicesEmergency Service, HospitalFemaleHealth LiteracyHumansHypertensionMaleMass SpectrometryMedication AdherenceMedication Therapy ManagementMiddle AgedUnited StatesConceptsElevated blood pressureSystolic blood pressureBlood pressureSystolic BPEmergency departmentBiochemical assessmentAntihypertensive adherenceAdherent patientsLower systolic blood pressureAntihypertensive medication adherenceHigher systolic BPPrimary care providersBody mass indexCross-sectional studyAntihypertensive nonadherenceNonadherent patientsPrimary outcomeED careMedication nonadherenceMass indexMedication adherenceAcademic hospitalCare providersAntihypertensivesBlood assaysGenetic Effects on the Correlation Structure of CVD Risk Factors Exome-Wide Data From a Ghanaian Population
Kodaman N, Sobota RS, Asselbergs FW, Oetjens MT, Moore JH, Brown NJ, Aldrich MC, Williams SM. Genetic Effects on the Correlation Structure of CVD Risk Factors Exome-Wide Data From a Ghanaian Population. Global Heart 2017, 12: 133-140. PMID: 28408189, PMCID: PMC5642993, DOI: 10.1016/j.gheart.2017.01.013.Peer-Reviewed Original ResearchConceptsPlasminogen activator inhibitor-1CVD risk factorsRisk factorsCardiovascular disease risk factorsDisease risk factorsHigh blood pressureActivator inhibitor-1Dissolution of thrombusArterial pressureBlood pressureMyocardial infarctionPlasma concentrationsStudy participantsGhanaian populationInhibitor-1Significant heterogeneityHeterogeneity of correlationAfrican AmericansGenetic variantsGenetic association studiesDirect role
2016
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition
Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation 2016, 133: 1115-1124. PMID: 26976916, PMCID: PMC4800749, DOI: 10.1161/circulationaha.115.018622.Peer-Reviewed Original ResearchMeSH KeywordsAbnormalities, Drug-InducedAminobutyratesAngioedemaAngiotensin Receptor AntagonistsBiphenyl CompoundsBradykininContraindicationsDrug CombinationsDrug CostsDrug SynergismEnalaprilEnzyme InhibitorsFemaleFollow-Up StudiesHeart FailureHumansHyperkalemiaHypertensionKidneyMulticenter Studies as TopicNatriuretic PeptidesNeprilysinPregnancyProdrugsProspective StudiesPyridinesRandomized Controlled Trials as TopicStroke VolumeTetrazolesThiazepinesValsartanConceptsValsartan/sacubitrilReduced ejection fractionHeart failureNatriuretic peptideEjection fractionN-terminal pro-brain natriuretic peptideNeprilysin inhibitor prodrug sacubitrilPro-brain natriuretic peptideAngiotensin receptor blocker valsartanAngiotensin receptor antagonismAngiotensin receptor blockersHeart Failure TrialReceptor blocker valsartanAngiotensin receptor antagonistsBrain natriuretic peptideOngoing clinical trialsMechanism of actionNeprilysin inhibitionAldosterone antagonistsAldosterone systemReceptor blockersBlood pressureFailure TrialPathophysiological mechanismsReceptor antagonism
2014
Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans
Laffer CL, Elijovich F, Eckert GJ, Tu W, Pratt JH, Brown NJ. Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans. International Journal Of Cardiology Cardiovascular Risk And Prevention 2014, 8: 475-480. PMID: 25064769, PMCID: PMC4115247, DOI: 10.1016/j.jash.2014.04.011.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBlack or African AmericanBlood PressureCytochrome P-450 CYP4ACytochrome P-450 Enzyme SystemDNADouble-Blind MethodFemaleGenetic VariationGenotypeHumansHypertensionMaleMiddle AgedMineralocorticoid Receptor AntagonistsPilot ProjectsRadioimmunoassayUnited StatesYoung AdultConceptsBlood pressure responseBlood pressureReceptor antagonismPressure responseMineralocorticoid receptor antagonismSalt-sensitive hypertensionAfrican AmericansExploratory pilot studyGC individualsAldosterone responseResistant hypertensionAntihypertensive effectTreatment responsePrecluded analysisCC genotypeCC homozygotesSpironolactoneC alleleHypertensionPilot studyENaC activationCYP4A11AmilorideActivation of ENaC.ENaC inhibition
2013
Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension
Gilbert K, Nian H, Yu C, Luther JM, Brown NJ. Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. Journal Of Hypertension 2013, 31: 820-829. PMID: 23385647, PMCID: PMC3800119, DOI: 10.1097/hjh.0b013e32835e8227.Peer-Reviewed Original ResearchConceptsBlood pressureSalt dietHeart ratePeroxisome proliferator-activated receptor α (PPARα) agonistSalt-resistant hypertensionPlasma renin activityRenal vascular resistanceEffect of fenofibrateLow-salt dietMean arterial pressureHigh-salt dietDouble-blind protocolTreatment of hyperlipidemiaReceptor α agonistSalt sensitivityHypertensive volunteersRenal vasoconstrictionRenin activitySodium excretionVascular resistanceArterial pressureHypertensive individualsSalt intakeSystolic pressureTreatment arms
2012
Polymorphisms in the serum- and glucocorticoid-inducible kinase 1 gene are associated with blood pressure and renin response to dietary salt intake
Rao AD, Sun B, Saxena A, Hopkins PN, Jeunemaitre X, Brown NJ, Adler GK, Williams JS. Polymorphisms in the serum- and glucocorticoid-inducible kinase 1 gene are associated with blood pressure and renin response to dietary salt intake. Journal Of Human Hypertension 2012, 27: 176-180. PMID: 22648267, PMCID: PMC3463709, DOI: 10.1038/jhh.2012.22.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersBlood PressureChi-Square DistributionEuropeFemaleGene FrequencyGenetic Predisposition to DiseaseHumansHypertensionImmediate-Early ProteinsLinear ModelsLinkage DisequilibriumLogistic ModelsMaleMiddle AgedPhenotypePolymorphism, Single NucleotideProtein Serine-Threonine KinasesReninRenin-Angiotensin SystemSodium Chloride, DietaryUnited StatesWhite PeopleConceptsDietary salt intakeBlood pressureSalt intakeSingle nucleotide polymorphismsHigher systolic blood pressureMeasurement of BPAldosterone system activityRAA system activitySystem activitySystolic blood pressureSalt-sensitive hypertensionSGK1 gene variantGlucocorticoid-inducible kinase 1Non-significant trendNormotensive populationRenin responseEpithelial sodium channelHuman hypertensionGenotype statusStudy populationDistal nephronHypertensionAdditive genetic modelSodium channelsGene variantsLysine-Specific Demethylase 1: An Epigenetic Regulator of Salt-Sensitive Hypertension
Williams JS, Chamarthi B, Goodarzi MO, Pojoga LH, Sun B, Garza AE, Raby BA, Adler GK, Hopkins PN, Brown NJ, Jeunemaitre X, Ferri C, Fang R, Leonor T, Cui J, Guo X, Taylor KD, Chen Y, Xiang A, Raffel LJ, Buchanan TA, Rotter JI, Williams GH, Shi Y. Lysine-Specific Demethylase 1: An Epigenetic Regulator of Salt-Sensitive Hypertension. American Journal Of Hypertension 2012, 25: 812-817. PMID: 22534796, PMCID: PMC3721725, DOI: 10.1038/ajh.2012.43.Peer-Reviewed Original ResearchConceptsMinor allele carriersSalt-sensitive hypertensionBlood pressureSingle nuclear polymorphismsAllele carriersHypertensive cohortDietary saltWT miceLiberal salt dietLiberal salt intakeSystolic blood pressureSerum aldosterone concentrationHeterozygote knockout miceTranslational research studiesRenovascular responsivenessAldosterone concentrationSalt dietDietary sodiumSalt intakeSystolic BPHuman studiesHypertensionKnockout miceClinical relevanceCaucasian cohortCardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies
Brown NJ. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. International Journal Of Cardiology Cardiovascular Risk And Prevention 2012, 6: 163-168. PMID: 22433315, PMCID: PMC3422131, DOI: 10.1016/j.jash.2012.02.003.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Cardiovascular eventsDipeptidyl peptidase IV inhibitorsAntidiabetic agentsPeptidase IV inhibitorsBlood pressureClinical trialsPeptide-1Animal modelsType 2 diabetes mellitusIncretin-based agentsBlood pressure effectsIncretin-based therapiesIV inhibitorsLarge clinical trialsFavorable effectIschemia/reperfusionTight glucose controlOverweight diabeticsCardiovascular effectsCardiovascular riskDiabetes mellitusIntensive therapyGlucose controlThiazolidinedione rosiglitazoneDifferential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome
Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome. Hypertension 2012, 59: 893-898. PMID: 22353614, PMCID: PMC3402551, DOI: 10.1161/hypertensionaha.111.189589.Peer-Reviewed Original ResearchConceptsEffects of nebivololMetabolic syndromeBlood pressureInsulin sensitivityPlasminogen activator inhibitorAntagonist metoprololGlucose homeostasisThird-generation β-blockerActivator inhibitorMarkers of fibrinolysisCongestive heart failureDiastolic blood pressureLower blood pressureSystolic blood pressureCoronary artery diseaseGlucose tolerance testLarge clinical trialsDetrimental metabolic effectsPlasminogen activator inhibitor-1Insulin sensitivity indexAcute insulin responseΒ-cell functionActivator inhibitor-1Study drugArtery disease
2011
CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow
Williams JS, Hopkins PN, Jeunemaitre X, Brown NJ. CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow. Journal Of Hypertension 2011, 29: 1913-1918. PMID: 21873888, PMCID: PMC3309034, DOI: 10.1097/hjh.0b013e32834aa786.Peer-Reviewed Original ResearchConceptsMean arterial pressureHigh salt intakeRenal blood flowHypertensive individualsBlood pressureSalt intakeC alleleSalt restrictionNormotensive individualsBlood flowSalt-sensitive blood pressureSalt sensitivityLow-salt dietDiagnosis of hypertensionHigh blood pressureSalt-sensitive hypertensionRenal vasodilationPressor responseSalt dietArterial pressureAngiotensin IIAttenuated increaseSodium homeostasisCYP4A11 T8590C polymorphismHypertension
2010
Low-salt diet increases insulin resistance in healthy subjects
Garg R, Williams GH, Hurwitz S, Brown NJ, Hopkins PN, Adler GK. Low-salt diet increases insulin resistance in healthy subjects. Metabolism 2010, 60: 965-968. PMID: 21036373, PMCID: PMC3036792, DOI: 10.1016/j.metabol.2010.09.005.Peer-Reviewed Original ResearchConceptsLow-salt dietHomeostasis model assessment indexModel assessment indexBody mass indexInsulin resistanceLS dietUrine aldosteroneMass indexHS dietHealthy subjectsHigher homeostasis model assessment indexUrine norepinephrine excretionPlasma renin activityHigh-salt dietSympathetic nervous systemSerum angiotensin IIPathogenesis of diabetesUrine epinephrineNorepinephrine excretionRenin activitySerum aldosteroneBlood pressureSerum sodiumAngiotensin IIHealthy menInteractive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans. Hypertension 2010, 56: 728-733. PMID: 20679179, PMCID: PMC3305047, DOI: 10.1161/hypertensionaha.110.156554.Peer-Reviewed Original ResearchMeSH KeywordsAdultAldosteroneAngiotensin-Converting Enzyme InhibitorsBlood GlucoseBlood PressureDiabetes Mellitus, Type 2Dipeptidyl Peptidase 4Dose-Response Relationship, DrugDouble-Blind MethodDrug InteractionsDrug Therapy, CombinationEnalaprilFemaleHeart RateHemodynamicsHumansInsulinMaleMetabolic SyndromeMiddle AgedPeptidyl-Dipeptidase AProspective StudiesPyrazinesRenal CirculationSitagliptin PhosphateSodiumTriazolesConceptsDipeptidyl peptidase IV inhibitionACE inhibitionHypotensive responseHemodynamic effectsBlood pressureHeart rateSerum dipeptidyl peptidase IV activityAngiotensin-Converting Enzyme InhibitionAcute ACE inhibitionVasoconstrictor neuropeptide YBlood pressure responseRenal blood flowSympathetic nervous systemType 2 diabeticsCross-over fashionDipeptidyl peptidase IV inhibitorsDose-dependent effectDipeptidyl peptidase IV activityDose-dependent mannerPeptidase IV inhibitorsPeptidase IV activityMetabolic syndromeNorepinephrine concentrationsIncretin hormonesNeuropeptide Y